Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1625 1626 1629 1691
This examiner grants 48% of resolved cases
Lauren Quinlan Wells has resolved 247 cases in Art Unit 1622, with an allowance rate of 48.2 percent. The median days to allowance is 1107, reflecting the complexities often found in Tech Center 1600. This allowance rate suggests that many cases do not reach a grant, indicating a rigorous examination process. Practitioners should be prepared for a challenging prosecution cycle of 1107 days.
However, the interview lift of 59.8 percent is very high. This metric indicates that an interview can significantly increase the chances of success compared to the 48.2 percent baseline. For practitioners, an interview is a critical strategic tool to overcome the examiner's initial objections and secure an allowance. The 59.8 percent lift is a powerful indicator that direct dialogue is an effective way to resolve disagreements in this docket. Despite the 1107-day median pendency, an early interview could significantly improve the odds of a favorable outcome. The data across 247 cases shows that while the examiner is strict, they are also highly receptive to the interview process, making verbal engagement a priority.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18835859 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 19635110 | PHARMACEUTICAL SOLUTION FOR ORAL DOSAGE | Final Rejection | LIQMEDS WORLDWIDE LIMITED |
| 18630042 | ACCESSING AND MODULATING THE COLOR AND VIBRANCY OF ANODICALLY COLORING ELECTROCHROMIC MOLECULES | Non-Final OA | Georgia Tech Research Corporation |
| 18859397 | SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE | Non-Final OA | Genentech, Inc. |
| 18003431 | HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY | Final Rejection | The Regents of the University of Michigan |
| 18720716 | COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18530612 | METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY | Non-Final OA | Massachusetts Institute of Technology |
| 18903075 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Non-Final OA | Vanderbilt University |
| 18706095 | USE OF APOMORPHINE AS THERAPEUTIC AGENT FOR NECROPTOSIS-RELATED DISEASES | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 17588104 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18109406 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18794321 | METHODS TO TREAT RENAL DISORDERS USING CALCIUM CHANNEL INHIBITORS | Non-Final OA | The Trustees of Indiana University |
| 18664869 | UNIFIED SYNTHETIC ENTRY TO AZASPIRO 3.N ALKANES | Non-Final OA | The Florida State University Research Foundation, Inc. |
| 17904393 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 | Non-Final OA | UCL BUSINESS PLC |
| 18834032 | METHOD FOR INACTIVATING VIRUSES OR BACTERIA | Non-Final OA | Kao Corporation |
| 18762266 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 18157438 | METHODS AND SYNERGIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | Non-Final OA | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. |
| 18888396 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | Non-Final OA | Ting Therapeutics, Inc. |
| 18288692 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | Final Rejection | City of Hope |
| 18782803 | METHOD FOR TREATMENT OF CANCER WITH COMBINATION OF COLD ATMOSPHERIC PLASMA AND A GENE INHIBITOR | Non-Final OA | Jerome Canady Research Institute for Advanced Biological and Technological Sciences |
| 18013856 | REDUCTION OF VIRAL INFECTIONS | Final Rejection | PHOXBIO LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy